-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…
-
Xeljanz: Drug-induced Peripheral Neuropathy as Possible Xeljanz Side Effect in 2 RA Patients
Reports of Rheumatoid Arthritis Patients on Xeljanz Experiencing Secondary Neurological Adverse Events (Posted by Tom Lamb at Drug Injury Watch) As we have written about previously, according to the FDA, some of the generally recognized…
-
Padcev Skin Reaction Side Effects SJS and TEN: From No Warning to “Black Box” in Less Than 2 Years
Bladder Cancer Drug Padcev is Linked to Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in 2021 (Posted by Tom Lamb at Drug Injury Watch) Padcev (enfortumab vedotin-ejfv), an injection drug for intravenous use, was…
-
Elmiron and Maculopathy: Increased Risk of Ocular Complications in Long-Term, High-Dose Elmiron Use
Two Recent Medical Articles on Vision Side Effects of Elmiron (pentosan polysulfate sodium, or PPS) for Interstitial Cystitis (Posted by Tom Lamb at Drug Injury Watch) Chronic use of Elmiron (pentosan polysulfate sodium, or PPS)…
-
Xeljanz: FDA Warnings Updated: There are Higher Rates of Blood Clots and Deaths for Both Doses of Xeljanz, Now
JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021 (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, the FDA released this alerting news…